Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1441-1447

  Dorin, Ryan P ^a   Lieskovsky, Gary ^a   Fairey, Adrian S ^a   Cai, Jie ^a   Daneshmand, Siamak ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Lymph node; Metastasis; Prostate cancer; Recurrence; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENCE FREE SURVIVAL;

LYMPH NODE; METASTASIS; PROSTATE CANCER; RECURRENCE; SURVIVAL;

AGED; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PELVIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84886308772     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.03.006     Document Type: Article

References (20)

1. Siegal R., Ward E., Brawley O., et al. Cancer statistics. CA Cancer J Clin 2011, 2011:212-236.
2. NCCN Clinical Practice guidelines in oncology: Prostate cancer version 4. 2011 National Comprehensive Cancer Network, Accessed 2011. http://www.nccn.org.
3. Briganti A., Blute M.L., Eastham J.H., et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 2009, 55:1251-1265.
4. Palapattu G.S., Allaf M.E., Trock B.J., et al. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: Results of long-term follow-up. J Urol 2004, 172:1860-1864.
5. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: Long-term results. J Urol 2004, 172:2252-2255.
6. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007, 178:864-871.
7. Bader P., Burkhard F.C., Markwalder R., et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance for cure?. J Urol 2003, 169:849-854.
8. Masterson T.A., Bianco F.J., Vickers A.J., et al. The association between total and positive lymph nodes counts, and disease progression in clinically localized prostate cancer. J Urol 2006, 175:1320-1324. discussion 1324.
9. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
10. Engel J., Bastian P.J., Baur H., et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010, 57:754-761.
11. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451.
12. Briganti A., Chun F.K., Salonia A., et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006, 98:788-793.
13. Allaf M.E., Palapattu G.S., Trock B.J., et al. Anatomical extent of lymph node dissection: Impact on men with clinically localized prostate cancer. J Urol 2004, 172:1840-1844.
14. Heidenreich A., Ohlmann C.H., Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007, 52:29-37.
15. Wagner M., Sokoloff M., Daneshmand S. The role of pelvic lymphadenectomy for prostate cancer-therapeutic?. J Urol 2008, 179:408-413.
16. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55:261-270.
17. Schumacher M.C., Burkhard F.C., Thalmann G.N., et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54:344-352.
18. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001, 28:555-556.
19. Ghavamian R., Bergstralh E.J., Blute M.L., et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: A matched comparison. J Urol 1999, 161:1223-1227. discussion 1227.
20. Grimm M.O., Kamphausen S., Hugenschmidt H., et al. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2002, 41:628-634.